B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B
暂无分享,去创建一个
J. Oldenburg | K. Pasi | K. Fischer | J. Mahlangu | A. Shapiro | B. Nolan | M. Ragni | T. Matsushita | A. Willemze | R. Kulkarni | D. Rudin | Huixing Yuan